Incubator at North Brunswick Tenants
Bright Cloud International Corp.
With academic roots in Rutgers University, Bright Cloud is a biomedical company focused in the fields of human-machine interface, virtual rehabilitation, remote rehabilitation, and integrative therapy. Its latest product, Bright Brainer, is a Class I FDA listed medical device that provides intensive game based motor training and cognitive exercising.
Calyptus Pharmaceutical’s is a research and development company with a mission to improve lives of patients by increasing access and affordability of quality medicines.
Calyptus empower the healthcare system by delivering pharmaceutical solutions that bridge unmet needs, resolve technological complexity, create accelerated regulatory pathways and overcome market access barriers.
Calyptus is laying the foundations of a specialty pharmaceutical business serving the needs of hospitals, community clinics, specialty, and retail pharmacies by delivering a portfolio of sterile products.
Delve Therapeutics is a discovery-stage startup researching novel oncolytic viruses.
Euprotein is a bioreagent company with a particular focus on developing recombinant proteins from mammalian cells for drug discovery applications. Euprotein also develops and implements mammalian cell based protein expression technology platforms for custom production services in support of biopharmaceutical drug development.
Fidelis Pharmaceuticals is a commercial stage, animal health company that provides GMP pharmaceuticals formulated specifically for laboratory animals
HistoBridge is a specialty preclinical and clinical research services organization committed to fulfill the histology and pathology needs for drug discovery/development.
Innovative Molecules is a drug discovery and contract research services company that will apply organic chemistry and biochemistry to optimize the pharmacotherapeutic utility of medicinal compounds.
JMS Pharma is a pharmaceutical contract development and manufacturing organization (CDMO) with focus on developing sterile formulations.”
Mito BioPharma is a biopharmaceutical company that focuses on targeting mitochondria and cellular metabolism modulation for development of therapeutics. Mitochondria are at the center of cellular metabolism and alteration in mitochondrial function contributes significantly to many diseases such as NASH, type 2 diabetes, lipid disorders, neurodegenerative diseases, cancer, and aging in general. It has long been proposed that these diseases could be effectively treated by modulating or correcting mitochondrial function. Mito BioPharma has a proprietary, small molecule-based technology and lead compounds that embody the therapeutic strategy of “correcting” or modulating such mitochondrial functions. The company expects this technology to have major impact on developing novel drugs in these therapeutic areas. Currently, the company is prioritizing liver-based diseases such as NASH, type 2 diabetes and certain liver-based orphan drug diseases. The company is currently in the lead finding phase with the anticipation of initiating IND-enabling studies in 2017. Moreover, the R&D team is generating an extended pipeline of candidate compounds suitable for other indications such as cancer and neurodegenerative diseases in order to capture the full value of its platform technology. Mito Biopharma’s core technology has been exclusively licensed from Rutgers University.
Neoventech strives to be the recognized leader in topical drug and active cosmetic product development. Our dedicated R&D team has a combined of 70+ years’ experience in drug delivery, cosmetic and topical drug product development and their successful global commercialization. The mission is to assist you to transform innovative ideas into successful cosmetics or topicalpharmaceutical products to address the dermatological disorders and unmet consumer needs in skin health. Neoventech commits to partner with industrial leaders and to find better ways to deliver the high quality products and services in a timely manner.
OLI Technologies is revolutionizing end-stage renal disease treatment. Leveraging proprietary nanotechnologies, OLI is developing intelligent wearables that emulate the natural capabilities of healthy kidneys.
Osseoprint 3D has developed a proprietary platform to design 3D print patient-matched bone scaffolds for fast and simple bone reconstruction surgeries. Orthopedic, dental, cosmetic, and other surgeons can augment and reconstruct bone defects with precision, speed, and safety with this chair-side 3D printing technology.
Skunkworx Labs (SKWX) is an innovative biologic drug discovery company dedicated to creating therapeutics targeting cancer, inflammation, and infectious diseases. Our unique protein screening platforms provide greater combinatory diversity than what naturally occurs in nature. It reaches beyond visible biology producing truly synthetic possibilities. SKWX serves to fix biological problems by providing synthetic solutions through its NanoProtein and NanoAntibody Libraries. Skunkworx can generate candidate biologics from known and unknown targets, identify new targets and generate tools and agents to guide rational drug design.
Smirta Innovation Inc.
Smirta Innovations Inc. is a Digital Health company focused on bringing Machine learning and AI based platforms to optimize patient flow logistics within Cancer treatment Centers as well as assist pathologists in analyzing tissues to segment, measure and predict. Smirta Innovations is led by an experienced group of Health IT executives and physicians who have successfully developed and commercialized multiple Health IT products that were used by large Health Systems nationwide.
SPES Pharmaceuticals is an innovative pharmaceutical technology company dedicated to provide medications with improved clinical benefits and patient compliance through development of innovative formulation and drug delivery technologies.
Sonder Research X
Sonder Medicine Inc. is a biotechnology startup company focused on using advanced imaging technology to develop therapeutic solutions for ophthalmic diseases and cancer, exclusively licensed from Cornell University
TheWell Bioscience is a biotech company focusing to develop and commercialize novel cell culture and delivery systems to empower life science research. Our goal is to bridge the in vitro and in vivo studies with simple, versatile products and services to achieve better efficiency while reducing costs. A joyful spirit is a precious gift to us.